176 related articles for article (PubMed ID: 34978016)
1. PTEN promoter methylation predicts 10-year prognosis in hormone receptor-positive early breast cancer patients who received adjuvant tamoxifen endocrine therapy.
Fan Y; Xie G; Wang Z; Wang Y; Wang Y; Zheng H; Zhong X
Breast Cancer Res Treat; 2022 Feb; 192(1):33-42. PubMed ID: 34978016
[TBL] [Abstract][Full Text] [Related]
2. MiR-4653-3p and its target gene FRS2 are prognostic biomarkers for hormone receptor positive breast cancer patients receiving tamoxifen as adjuvant endocrine therapy.
Zhong X; Xie G; Zhang Z; Wang Z; Wang Y; Wang Y; Qiu Y; Li L; Bu H; Li J; Zheng H
Oncotarget; 2016 Sep; 7(38):61166-61182. PubMed ID: 27533459
[TBL] [Abstract][Full Text] [Related]
3. Region-specific glucocorticoid receptor promoter methylation has both positive and negative prognostic value in patients with estrogen receptor-positive breast cancer.
Snider H; Villavarajan B; Peng Y; Shepherd LE; Robinson AC; Mueller CR
Clin Epigenetics; 2019 Nov; 11(1):155. PubMed ID: 31675993
[TBL] [Abstract][Full Text] [Related]
4. PTEN protein expression in postmenopausal steroid receptor positive early breast cancer patients treated with adjuvant tamoxifen.
Milovanovic Z; Dzodic R; Susnjar S; Plesinac-Karapandzic V; Juranic Z; Tatic S
J BUON; 2011; 16(1):46-51. PubMed ID: 21674849
[TBL] [Abstract][Full Text] [Related]
5. Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer.
Fisher B; Jeong JH; Dignam J; Anderson S; Mamounas E; Wickerham DL; Wolmark N
J Natl Cancer Inst Monogr; 2001; (30):62-6. PubMed ID: 11773294
[TBL] [Abstract][Full Text] [Related]
6. Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapy.
Filipits M; Rudas M; Heinzl H; Jakesz R; Kubista E; Lax S; Schippinger W; Dietze O; Greil R; Stiglbauer W; Kwasny W; Nader A; Stierer M; Gnant MF;
Clin Cancer Res; 2009 Sep; 15(18):5888-94. PubMed ID: 19723645
[TBL] [Abstract][Full Text] [Related]
7. SHON expression predicts response and relapse risk of breast cancer patients after anthracycline-based combination chemotherapy or tamoxifen treatment.
Abdel-Fatah TMA; Broom RJ; Lu J; Moseley PM; Huang B; Li L; Liu S; Chen L; Ma RZ; Cao W; Wang X; Li Y; Perry JK; Aleskandarany M; Nolan CC; Rakha EA; Lobie PE; Chan SYT; Ellis IO; Hwang LA; Lane DP; Green AR; Liu DX
Br J Cancer; 2019 Apr; 120(7):728-745. PubMed ID: 30816325
[TBL] [Abstract][Full Text] [Related]
8. Role of Ki67 in predicting resistance to adjuvant tamoxifen in postmenopausal breast cancer patients.
Elzawahry HM; Saber MM; Mokhtar NM; Zeeneldin AA; Ismail YM; Alieldin NH
J Egypt Natl Canc Inst; 2013 Dec; 25(4):181-91. PubMed ID: 24207090
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer.
Bago-Horvath Z; Rudas M; Dubsky P; Jakesz R; Singer CF; Kemmerling R; Greil R; Jelen A; Böhm G; Jasarevic Z; Haid A; Gruber C; Pöstlberger S; Filipits M; Gnant M;
Clin Cancer Res; 2011 Dec; 17(24):7828-34. PubMed ID: 21998336
[TBL] [Abstract][Full Text] [Related]
10. The influence of PTEN protein expression on disease outcome in premenopausal hormone receptor-positive early breast cancer patients treated with adjuvant ovarian ablation: a long-term follow-up.
Ursulovic T; Milovanovic Z; Medic-Milijic N; Gavrilovic D; Plesinac-Karapandzic V; Susnjar S
J BUON; 2018; 23(4):902-909. PubMed ID: 30358192
[TBL] [Abstract][Full Text] [Related]
11. Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen.
Shoman N; Klassen S; McFadden A; Bickis MG; Torlakovic E; Chibbar R
Mod Pathol; 2005 Feb; 18(2):250-9. PubMed ID: 15475931
[TBL] [Abstract][Full Text] [Related]
12. Role of PTEN promoter methylation in tamoxifen-resistant breast cancer cells.
Phuong NT; Kim SK; Lim SC; Kim HS; Kim TH; Lee KY; Ahn SG; Yoon JH; Kang KW
Breast Cancer Res Treat; 2011 Nov; 130(1):73-83. PubMed ID: 21170675
[TBL] [Abstract][Full Text] [Related]
13. Toremifene, rather than tamoxifen, might be a better option for the adjuvant endocrine therapy in CYP2D6*10T/T genotype breast cancer patients in China.
Lan B; Ma F; Chen S; Wang W; Li Q; Fan Y; Luo Y; Cai R; Wang J; Yuan P; Zhang P; Li Q; Xu B
Int J Cancer; 2018 Nov; 143(10):2499-2504. PubMed ID: 29978573
[TBL] [Abstract][Full Text] [Related]
14. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.
Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC
Breast Cancer Res; 2014 Jan; 16(1):R13. PubMed ID: 24467828
[TBL] [Abstract][Full Text] [Related]
15. Breast cancer patients with estrogen receptor-negative/progesterone receptor-positive tumors: being younger and getting less benefit from adjuvant tamoxifen treatment.
Yu KD; Di GH; Wu J; Lu JS; Shen KW; Liu GY; Shen ZZ; Shao ZM
J Cancer Res Clin Oncol; 2008 Dec; 134(12):1347-54. PubMed ID: 18488249
[TBL] [Abstract][Full Text] [Related]
16. Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy.
Bartlett JM; Thomas J; Ross DT; Seitz RS; Ring BZ; Beck RA; Pedersen HC; Munro A; Kunkler IH; Campbell FM; Jack W; Kerr GR; Johnstone L; Cameron DA; Chetty U
Breast Cancer Res; 2010; 12(4):R47. PubMed ID: 20615243
[TBL] [Abstract][Full Text] [Related]
17. Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer.
Martens JW; Nimmrich I; Koenig T; Look MP; Harbeck N; Model F; Kluth A; Bolt-de Vries J; Sieuwerts AM; Portengen H; Meijer-Van Gelder ME; Piepenbrock C; Olek A; Höfler H; Kiechle M; Klijn JG; Schmitt M; Maier S; Foekens JA
Cancer Res; 2005 May; 65(10):4101-17. PubMed ID: 15899800
[TBL] [Abstract][Full Text] [Related]
18. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial.
Fargeot P; Bonneterre J; Roché H; Lortholary A; Campone M; Van Praagh I; Monnier A; Namer M; Schraub S; Barats JC; Guastalla JP; Goudier MJ; Chapelle-Marcillac I
J Clin Oncol; 2004 Dec; 22(23):4622-30. PubMed ID: 15505276
[TBL] [Abstract][Full Text] [Related]
19. Recurrence-free survival in breast cancer improved by adjuvant tamoxifen--especially for progesterone receptor positive tumors with a high proliferation.
Fernö M; Baldetorp B; Bendahl PO; Borg A; Ewers SB; Olsson H; Rydén S; Sigurdsson H; Killander D
Breast Cancer Res Treat; 1995; 36(1):23-34. PubMed ID: 7579503
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer.
Li L; Chang B; Jiang X; Fan X; Li Y; Li T; Wu S; Zhang J; Kariminia S; Li Q
BMC Cancer; 2018 Oct; 18(1):977. PubMed ID: 30314452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]